News | November 01, 2024
Supriya Lifescience reports 19% revenue increase in Q2 FY25
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
